Progyny (PGNY) Cash & Equivalents (2018 - 2026)

Progyny (PGNY) has reported Cash & Equivalents for 9 consecutive years, with $131.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 20.48% year-over-year to $131.6 million; the TTM figure through Mar 2026 stood at $131.6 million (up 20.48% YoY), while the FY2025 annual figure was $112.2 million, down 30.85% from the prior year.
• Cash & Equivalents climbed to $131.6 million in Q1 2026 per PGNY's latest filing, from $112.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $170.6 million in Q2 2023 and bottomed at $38.8 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $114.7 million across 5 years, with a median of $115.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 300.09% — and 2024, when it plunged 44.33%.
• Progyny's Cash & Equivalents stood at $120.1 million in 2022, then declined by 18.97% to $97.3 million in 2023, then jumped by 66.82% to $162.3 million in 2024, then slumped by 30.85% to $112.2 million in 2025, then increased by 17.26% to $131.6 million in 2026.
• Business Quant data shows PGNY's Cash & Equivalents at $131.6 million in Q1 2026, $112.2 million in Q4 2025, and $134.0 million in Q3 2025.